Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858443 | 1.00 | LOXL2 (0.53) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL13359301 | 0.85 | LOXL2 (0.51) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL7848451 | 0.83 | LOXL2 (0.50) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL3640241 | 0.82 | LOXL2 (0.49) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL11229238 | 0.81 | CASR (0.44) | LOXL2ADAMTS4MTNR1AMTNR1BCASR | |
| SCHEMBL5859102 | 0.81 | LOXL2 (0.47) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL5857940 | 0.81 | LOXL2 (0.47) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL5365001 | 0.81 | LOXL2 (0.55) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL5249054 | 0.81 | LOXL2 (0.55) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B | |
| SCHEMBL30305027 | 0.81 | LOXL2 (0.55) | LOXL2ADAMTS4DPP4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049432-B2 | Oligonucleotides having alkylphosphonate linkages and methods for their preparation | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-0904275-B1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | UNIV MCGILL (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-6861518-B2 | Hybrid oligonucleotide | MCGILL UNIVERSITY (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | JUST GEORGE (CA) | 2003-06-19 | — | — | US | disclosed |
| US-20030078414-A1 | Oligonucleotides having alkylphosphonate linkages and methods for their preparation | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6486313-B1 | Oligonucleotides having alkylphosphonate linkages and methods for their preparation | ISIS PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6476216-B1 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 2002-11-05 | — | — | US | disclosed |
| EP-1169329-A4 | OLIGONUCLEOTIDES HAVING ALKYLPHOSPHONATE LINKAGES AND METHODS FOR THEIR PREPARATION | ISIS PHARMACEUTICALS INC (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1169329-A1 | OLIGONUCLEOTIDES HAVING ALKYLPHOSPHONATE LINKAGES AND METHODS FOR THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6160109-A | Preparation of phosphorothioate and boranophosphate oligomers | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000049032-A1 | OLIGONUCLEOTIDES HAVING ALKYLPHOSPHONATE LINKAGES AND METHODS FOR THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000000499-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES WITH BORANOPHOSPHATE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| EP-0904275-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | McGILL UNIVERSITY (CA) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997014710-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | MCGILL UNIVERSITY (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | LOXL2 3855/4885ADAMTS4 1960/4885DPP4 2630/4885 |
| US-20030078414-A1 | Oligonucleotides having alkylphosphonate linkages and methods for their preparation | POLM, PPIP5K2, POLRMT | LOXL2 3062/4885ADAMTS4 4615/4885DPP4 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.